The wide variety of contract services featured include device strategy, product development and manufacture across specialty drug delivery devices, dosing systems, disposable insulin pens, blood glucose meters, inhalators, multi-component dosing units, spray applicators, right up to wearable drug delivery devices designed to improve patient engagement and drive better outcomes.
Visitors to Phillips-Medisize’s stand will have the opportunity to discuss with Bill Welch, Chief Technology Officer, and his colleagues the technological progress in connected drug delivery devices. The use of electronic functional components is becoming a new crucial prerequisite to facilitate the patients’ drug administration, to ensure precise dosing quantity and timing, and predominantly to raise drug delivery to higher safety standards. The rise in complexity of a drug delivery device results in exponential growth of important factors which have to be considered when following the individual steps of the entire value-creation chain. On 2nd February, Bill Welch will give a lecture from 14:25 to 14:50 h entitled “Drug Delivery and Connectivity Challenge”. The entire range of topics he will refer to is outlined within the Pharmapack Agenda 02 Feb 2017: Pharmapack Agenda
Customers, prospects, and other interested parties can learn about the values and benefits of choosing a trusted outsource partner and will be informed how Phillips-Medisize can help turn an idea into a successful complex drug delivery device, as well as coverage of a value proposition and a strategic platform on the basis of several recently accomplished project examples. Further, as part of Molex, Phillips-Medisize is now able to provide turn- key manufacturing solutions for customers developing electro-mechanical drug delivery systems. Herein information will correspondingly cover the regulatory requirements which have to be met e.g. for a connected health device, its validation procedures and particular constraints imposed by the responsible authorities in the countries concerned. Another major focus is placed on design, development and manufacturing – from material selection to the first pilot batch and finally through to all aspects of clinical scaling and desired end scale. Bill Welch condensed this chain of progression into “... a harmonized roadmap for efficiency, compliance and speed to market.”
Phillips-Medisize offers its customers a complete service chain, from first ideas to finished solutions, from the design stage all the way to the ready-to-use sterile-wrapped products. The company’s strong point in the market is represented in particular by complex disposables, controlled across all processes through highly prioritized quality assurance measures compliant with ISO 13485 as well as FDA standards and GMP (Good Manufacturing Practice).